Pancreatitis risk with DPP4 inhibitors

Acute pancreatitis is now listed as a possible adverse effect of all dipeptidyl peptidase 4 (DPP4) inhibitors ('gliptins').

The mechanism by which DPP4 inhibitors might increase the risk of pancreatitis is unknown | SCIENCE PHOTO LIBRARY
The mechanism by which DPP4 inhibitors might increase the risk of pancreatitis is unknown | SCIENCE PHOTO LIBRARY

Drugs of this class, which are used in the treatment of type II diabetes, include Galvus (vildagliptin), Januvia (sitagliptin), Onglyza (saxagliptin), Trajenta (linagliptin), and the combination tablets Eucreas (metformin + vildagliptin), Janumet (metformin + sitagliptin) and Jentadueto (metformin + linagliptin).

When to suspect pancreatitis

Characteristic symptoms of acute pancreatitis include persistent, severe abdominal pain, sometimes radiating to the back. The MHRA advises that all patients taking a DPP4 inhibitor should be informed of these symptoms and encouraged to report any occurrence. Treatment should be discontinued if pancreatitis is suspected. 

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Additional tiotropium inhaler available to prescribe

Additional tiotropium inhaler available to prescribe

Acopair is delivered by the dry powder NeumoHaler device.

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

New products - live tracker

New products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products added...

New and deleted indications - live tracker

New and deleted indications - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest changes to...